RELMADA THERAPEUTICS, INC. 8-K — AI Bull & Bear Analysis

Relmada's 8-K filing reveals a company at a critical juncture, balancing the need for aggressive growth capital against the risk of severe shareholder dilution. The approval of the charter amendment to increase authorized shares provides the necessary 'currency' for the company to operate, but the uneven support for the equity incentive plan suggests a fractured relationship with its investor base. The overall impact is a net increase in management's ability to raise capital, which is essential for biotech survival but potentially detrimental to current per-share value.